Dual GLP-1 + GIP receptor agonist (codename for restricted compound)
GLP-2 (MNJ)
Dual GLP-1 and GIP receptor agonist studied for body-composition research.
- Half-life~5 days, supports once-weekly dosing
- Dose rangeTitrate from 2.5 mg/wk to 15 mg/wk over 20 weeks
- Reconstituted stability28 days, 2–8 °C
- VerificationCOA included
Mechanism
How it works.
Activates GLP-1 and GIP receptors simultaneously. Slows gastric emptying, increases satiety, improves insulin sensitivity, and modulates lipid metabolism through the GIP arm.
Research
What the research shows.
Phase 3 SURMOUNT-1 trial showed average 22.5% weight reduction at 72 weeks at the 15 mg dose. GI side-effect profile is similar to single-receptor GLP-1 line.
GLP-2 (MNJ) is the codename for a dual GLP-1 plus GIP receptor agonist. The dual-receptor mechanism produces larger metabolic effects in published Phase 3 trials than the single-receptor GLP-1 line at matched cohorts.
The compound is research-grade only at NuroCore. The licensed-medicine version exists in a different regulatory category. Within the research-context catalogue, the dose patterns mirror the published trial protocols with a graduated titration designed to minimise GI side effects.
Contraindications
When not to use.
Personal/family history of medullary thyroid carcinoma or MEN-2. Active pancreatitis. Pregnancy. Severe renal impairment.
Optimal pairings
Stacks well with.
Information is educational, derived from published research. Not medical advice. All compounds sold for research use only. Bloodwork and a clinical consultation should precede any new protocol.